Skip to content

A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).

A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03180346
Enrollment
494
Registered
2017-06-08
Start date
2017-03-21
Completion date
2021-03-31
Last updated
2017-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Incision

Brief summary

The primary aim of this study is to determine if the SSI rate following revision total hip and knee arthroplasty is reduced in patients treated with the PICO device compared to patients with traditional postoperative dressings. Our secondary goals include; comparing the amount of wound drainage, rate of resolution of wound drainage, length of hospital stay, functional outcomes, and economic implications of wound drainage and SSI after revision arthroplasty comparing PICO and traditional dressings.

Interventions

DEVICEPICO

Single Use Negative Pressure Dressing

DEVICEAquacel

Occlusive surgical dressing infused with ionized silver

Sponsors

Rothman Institute Orthopaedics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient ≥18 years old 2. Male or non-pregnant, non-lactating, postmenopausal or surgically sterilized females 3. Subjects undergoing revision total knee arthroplasty or revision total hip arthroplasty 4. Subjects provide informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information 5. Subjects deemed able to understand and comply with study visit schedule and procedures

Exclusion criteria

1. Wounds that require daily inspection 2. Active bleeding within the surgical site 3. Pregnant, lactating females, or females of childbearing potential not willing to practice an effective method of contraception 4. Subjects on warfarin therapy. Resulting in increased exudate and prolonging hospital stay following surgery to achieve therapeutic INR levels 5. Skin integrity issues that preclude the use of Negative Pressure Wound Therapy (NPWT) 6. Subjects undergoing primary total joint procedures 7. Subjects with a known history of poor compliance with medical treatment 8. Subjects who have participated in this trial previously and who were withdrawn 9 . Subjects with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing)

Design outcomes

Primary

MeasureTime frame
Surgical Site Infection90-day followup following revision surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026